CRBP

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Corbus Pharmaceuticals reported positive topline CANYON-1 results for daily oral CRB-913 in obesitySep 14, 2026
• Corbus Pharmaceuticals completed the last patient last visit in the CANYON-1 obesity study of CRB-913Aug 4, 2026
• Corbus Pharmaceuticals receives FDA clearance to begin the registrational TEMPO-1 study of CRB-701 in second-line oropharyngeal cancerJul 28, 2026
• Corbus Pharmaceuticals reports updated Phase 1/2 data showing strong activity of CRB-701 in cancer patientsMay 26, 2026
• Corbus completed last patient first visit in the CANYON-1 obesity study of CRB-913Apr 14, 2026